AbbVie’s Combination Therapy: ABT-450, ABT-333, and ABT-267 (Hepatitis C Virus)：市場予測と分析（～2022）...市場調査レポートについてご紹介

1 Table of Contents
1 Table of Contents 4
1.1 List of Tables 7
1.2 List of Figures 7
2 Introduction 8
2.1 Catalyst 8
2.2 Related Reports 8
2.3 Upcoming Related Reports 9
3 Disease Overview 10
3.1 Etiology and Pathophysiology 10
3.1.1 Etiology 10
3.1.2 Pathophysiology 14
3.1.3 Prognosis 15
3.2 Symptoms 15
4 Disease Management 16
4.1 Diagnosis and Referral Overview 16
4.2 Treatment Overview 17
5 Competitive Assessment 20
5.1 Overview 20
5.2 Strategic Competitor Assessment 20
6 Opportunity and Unmet Need 22
6.1 Overview 22
6.2 Unmet Needs 23
6.2.1 Unmet Need: Treatment Tolerability 23
6.2.2 Unmet Need: Efficacy 23
6.2.3 Unmet Need: Disease Awareness 24
6.2.4 Unmet Need: Treatment Cost 25
6.2.5 Unmet Need: Shorter Treatment Duration 25
6.2.6 Unmet Need: Simplified Treatment Regimens 26
6.3 Unmet Needs Gap Analysis 26
6.4 Opportunities 27
6.4.1 Opportunity: Pan-genotypic HCV Regimen 27
6.4.2 Opportunity: Treatment of Underrepresented Patient Populations 27
6.4.3 Opportunity: Involvement of Immune System 28
7 Pipeline Assessment 29
7.1 Overview 29
7.2 Promising Drugs in Clinical Development 30
8 AbbVie’s Combination Therapy: ABT-450, ABT-333, and ABT-267 32
8.1 Overview 32
8.2 Efficacy 34
8.3 Safety 35
8.4 Dosing and Formulation 35
8.5 Potential Clinical Positioning 36
8.6 Potential Commercial Positioning 36
8.7 Pricing and Reimbursement 37
8.8 SWOT Analysis 37
8.9 Forecast 39
9 Appendix 40
9.1 Bibliography 40
9.2 Abbreviations 42
9.3 Methodology 43
9.4 Forecasting Methodology 43
9.4.1 Percent Drug-Treated Patients 43
9.4.2 Patient Warehousing 44
9.4.3 General Pricing Assumptions 44
9.4.4 Generic Erosion 45
9.4.5 Pricing of Pipeline Agents 45
9.5 Physicians and Specialists Included in this Study 46
9.6 Survey of Prescribing Physicians 48
9.7 About the Authors 49
9.7.1 Author 49
9.7.2 Global Head of Healthcare 49
9.8 About GlobalData 50
9.9 Contact Us 50
9.10 Disclaimer 50